Abstract: The present invention provides N-methylated cyclic hexapeptides comprising RGD and at least one alanine residue. The present invention further provides prodrugs comprising the cyclic hexapeptides. Pharmaceutical compositions comprising said cyclic hexapeptides are also disclosed as well as methods of their production and use in treating integrin related conditions and diseases.

Abstract: The present invention concerns a solid oral dosage form comprising albumin and at least one cannabinoid, wherein the oral dosage form is free of a gas generating agent (GGA) and wherein the oral dosage form is prepared using a compression force Q of below 1 ton.

Abstract: The present invention provides peptides derived from the cytoplasmic region of protease-activated receptors 4 (PAR4) as well as analogs and cyclic analogs, such as backbone cyclic analogs, of these peptides. Pharmaceutical compositions comprising said peptides, analog, cyclic analogs and well as conjugates thereof are provided as well. The peptides, analogs and conjugates of the present invention and pharmaceutical composition comprising thereof have several uses including treating cancer such as cancer expressing PAR proteins such as cancer expressing ErbB protein and triple negative cancer. and inhibiting interactions between PARs and protein comprising PH-domain.

Abstract: The invention provides devices, formulations, and methods for systemic delivery of agents in the oral and buccal cavity and the gastrointestinal system, including immediate and prolonged drug delivery. The invention is particularly applicable to poorly water-soluble agents and drugs.

Abstract: The present invention provides peptides derived from the cytoplasmic region of protease-activated receptors 4 (PAR4) as well as analogs and cyclic analogs, such as backbone cyclic analogs, of these peptides. Pharmaceutical compositions comprising said peptides, analog, cyclic analogs and well as conjugates thereof are provides as well. The peptides, analogs and conjugates of the present invention and pharmaceutical composition comprising thereof have several uses including treating cancer and inhibiting interactions between PARs and protein comprising PH-domain.

Abstract: The present invention provides prodrugs of somatostatin peptide and peptide analogs that are tissue permeable and oral bioavailable and enable activity of the somatostatin analog at the circulation or target tissue after cleavage of charge-masking lipophilic moieties. Pharmaceutical compositions comprising these prodrugs and their use in therapy and diagnosis are also provided.

Abstract: The present invention relates to methods of preparing peptide-based prodrugs having enhanced oral bioavailability and intestinal penetration. Said prodrugs are characterized in improved lipophilicity, reduced electric charge and tendency to undergo biotransformation through enzymatic reaction (e.g. in the blood stream) to form biologically active peptides.

Abstract: Provided herein are compositions of injectable antibiotics for veterinary use. The compositions are characterized by forming a gel at animal physiological temperature, said gel being characterized by a stable and repeatable release profile of the antibiotic. The compositions comprise high loading of drug in poloxamer solutions with addition of a co-solvent, and preferably with an addition of a cellulose derivative at least partially soluble in organic solvents. Methods of treatment of veterinary infections are also provided.

Abstract: A composition which comprises a biologically active agent and a polymer that exhibits a reverse thermal gelation at a physiological temperature, in a carrier, and in which the active agent is in an undissolved form is disclosed herein. Further disclosed herein are methods utilizing the compositions for treating subjects, including non-human subjects, as well as kits for preparing and using a composition. The composition is preferably a sustained release formulation, and is particularly useful for treating animals, where single-dose treatment is desired.

Abstract: The present invention relates to methods of preparing peptide-based prodrugs having enhanced oral bioavailability and intestinal penetration. Said prodrugs are characterized in improved lipophilicity, reduced electric charge and tendency to undergo biotransformation through enzymatic reaction (e.g. in the blood stream) to form biologically active peptides.

Abstract: The present invention provides N-methylated cyclic hexapeptides comprising RGD and at least one alanine residue. The present invention further provides prodrugs comprising the cyclic hexapeptides. Pharmaceutical compositions comprising said cyclic hexapeptides are also disclosed as well as methods of their production and use in treating integrin related conditions and diseases.

Abstract: The present invention provides prodrugs of somatostatin peptide and peptide analogs that are tissue permeable and oral bioavailable and enable activity of the somatostatin analog at the circulation or target tissue after cleavage of charge-masking lipophilic moieties. Pharmaceutical compositions comprising these prodrugs and their use in therapy and diagnosis are also provided.

Abstract: Provided are backbone cyclized peptides that interfere with signaling of the intracellular adaptor protein MyD88. Pharmaceutical compositions including these backbone cyclized peptides as well as their use in treatment of multiple sclerosis (MS) and other diseases associated with MyD88 signaling are also disclosed.

Abstract: Provided is a formulation and method for increasing bioavailability of an orally administered drug.

Abstract: Provided are backbone cyclized peptides that interfere with signaling of the intracellular adaptor protein MyD88. Pharmaceutical compositions including these backbone cyclized peptides as well as their use in treatment of multiple sclerosis (MS) and other diseases associated with MyD88 signaling are also disclosed.

Abstract: Provided are formulations and methods for improving oral bioavailability of cannabinoid compositions.

Abstract: The present invention relates to methods and compositions for treating disease related to disorders of bone remodeling. In particular, the present invention relates to compositions and methods for treating rheumatoid arthritis.

Abstract: The present invention provides compositions and methods for inducing an immune response in a subject. In particular, the present invention provides compositions comprising immunostimulatory ligands (ISL) and methods of inducing an immune response in a subject therewith. Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.

Abstract: The present invention relates to methods and compositions for treating disease related to disorders of bone remodeling. In particular, the present invention relates to compositions and methods for treating rheumatoid arthritis.

Abstract: The present invention relates to novel metalloproteinase inhibitors having an aryloxybenzenesulfonamide moiety and a carbamoylphosphonic acid moiety, to pharmaceutical compositions comprising them, and to their uses in the prevention and/or treatment of disease or disorder associated with MMP.